EP1339751A4 - Fragments d'anticorps de recombinaison utilises comme antagonistes d'auto-anticorps - Google Patents

Fragments d'anticorps de recombinaison utilises comme antagonistes d'auto-anticorps

Info

Publication number
EP1339751A4
EP1339751A4 EP01979850A EP01979850A EP1339751A4 EP 1339751 A4 EP1339751 A4 EP 1339751A4 EP 01979850 A EP01979850 A EP 01979850A EP 01979850 A EP01979850 A EP 01979850A EP 1339751 A4 EP1339751 A4 EP 1339751A4
Authority
EP
European Patent Office
Prior art keywords
auto
antibody
antagonists
recombinant
antibody fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01979850A
Other languages
German (de)
English (en)
Other versions
EP1339751A2 (fr
Inventor
Budingen Hans-Christian Von
Claude Genain
Stephen Hauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of EP1339751A2 publication Critical patent/EP1339751A2/fr
Publication of EP1339751A4 publication Critical patent/EP1339751A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP01979850A 2000-10-17 2001-10-17 Fragments d'anticorps de recombinaison utilises comme antagonistes d'auto-anticorps Withdrawn EP1339751A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US691654 1991-04-25
US69165400A 2000-10-17 2000-10-17
US09/899,896 US6569431B2 (en) 2000-10-17 2001-07-05 Recombinant antibody fragments as autoantibody antagonists
US899896 2001-07-05
PCT/US2001/032234 WO2002033042A2 (fr) 2000-10-17 2001-10-17 Fragments d'anticorps de recombinaison utilises comme antagonistes d'auto-anticorps

Publications (2)

Publication Number Publication Date
EP1339751A2 EP1339751A2 (fr) 2003-09-03
EP1339751A4 true EP1339751A4 (fr) 2006-06-21

Family

ID=27104819

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01979850A Withdrawn EP1339751A4 (fr) 2000-10-17 2001-10-17 Fragments d'anticorps de recombinaison utilises comme antagonistes d'auto-anticorps

Country Status (6)

Country Link
US (1) US6569431B2 (fr)
EP (1) EP1339751A4 (fr)
JP (1) JP2004511570A (fr)
AU (2) AU1177102A (fr)
CA (1) CA2423073A1 (fr)
WO (1) WO2002033042A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412650C (fr) * 2000-06-14 2011-08-02 Georgetown University La pleiotrophine, recepteur d'un facteur de croissance, utilisable pour le traitement de troubles de nature proliferante, vasculaire et neurologique
AU2001295503A1 (en) * 2000-08-22 2002-03-04 Micromet Ag Composition for the elimination of autoreactive b-cells
ITFI20010144A1 (it) * 2001-07-25 2003-01-25 Univ Firenze Colonne per immunoassorbimento per sottrazione di autoanticorpi dal sangue con tecniche di plasmafiltrazione selettiva
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
ATE534669T1 (de) 2002-05-28 2011-12-15 Omrix Biopharmaceuticals Inc Verfahren zum erhalten von anti-idiotyp antikörpern
WO2004034031A2 (fr) * 2002-10-11 2004-04-22 The Regents Of The University Of California Methode permettant de diagnostiquer et de pronostiquer la sclerose en plaques
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
WO2005080985A2 (fr) * 2004-02-18 2005-09-01 Enteron Limited Partnership Methodes et compositions permettant de detecter et de traiter des maladies auto-immunes
RU2008110058A (ru) * 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Химерные антитела с областями приматов нового света
JP6152090B2 (ja) 2011-04-21 2017-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 視神経脊髄炎を処置するための組成物および方法
WO2013177116A1 (fr) * 2012-05-21 2013-11-28 The Regents Of The University Of California Modification enzymatique d'un auto-anticorps anti-aqp4 pour la modulation de la maladie de devic
CA3297793A1 (en) * 2016-12-26 2026-03-02 Kagoshima University Antibody which binds to myelin oligodendrocyte glycoprotein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012126A1 (fr) * 1998-08-26 2000-03-09 The Regents Of The University Of California Inhibiteurs d'auto-anticorps

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012126A1 (fr) * 1998-08-26 2000-03-09 The Regents Of The University Of California Inhibiteurs d'auto-anticorps

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KNAPPIK A ET AL: "FULLY SYNTHETIC HUMAN COMBINATORIAL ANTIBODY LIBRARIES (HUCAL) BASED ON MODULAR CONSENSUS FRAMEWORKS AND CDRS RANDOMIZED WITH TRINUCLEOTIDES", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 296, no. 1, February 2000 (2000-02-01), pages 57 - 86, XP002941688, ISSN: 0022-2836 *
LININGTON C ET AL: "THE ROLE OF COMPLEMENT IN THE PATHOGENESIS OF EXPERIMENTAL ALLERGICENCEPHALOMYELITIS", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 112, 1989, pages 895 - 911, XP002926246, ISSN: 0006-8950 *

Also Published As

Publication number Publication date
US20020072588A1 (en) 2002-06-13
JP2004511570A (ja) 2004-04-15
AU2002211771B8 (en) 2004-07-01
EP1339751A2 (fr) 2003-09-03
WO2002033042A2 (fr) 2002-04-25
AU1177102A (en) 2002-04-29
US6569431B2 (en) 2003-05-27
CA2423073A1 (fr) 2002-04-25
WO2002033042A3 (fr) 2002-07-04
AU2002211771B2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
EP1396500A4 (fr) Anticorps anti-trail-r
EP1423431A4 (fr) Anticorps anti-vla-1
ITMI20001884A0 (it) Procedimento integrato per la preparazione di ossidi olefinici
EP1294513A4 (fr) Bioconjugaison covalente, de restriction, de proteines
EP1339751A4 (fr) Fragments d'anticorps de recombinaison utilises comme antagonistes d'auto-anticorps
DE60105696D1 (de) Eisenhaltige Proteinzusammensetzung
EP1088831A4 (fr) Nouvelles proteines receptrices d'hemopo etine
FR2824092B1 (fr) Ensemble d'elements de construction
EP1171152A4 (fr) ANTAGONISTES PEPTIDIQUES vMIP-II DE CXCR4
DZ3333A1 (fr) Antagonistes de recepteurs d'il-8
EP1359932A4 (fr) Polypeptides tip39
EP1272205A4 (fr) Anticorps du facteur-2 de la sialoadhesine
NO20032963D0 (no) Peptidforbindelser
FR2810232B1 (fr) Ensemble orthopedique pour l'arthrodese de la hanche
EP1393746A4 (fr) Compositions d'anticorps polyclonaux humains
EP1455822A4 (fr) Compositions lyophilisees d'anticorps monoclonaux
ATE278712T1 (de) Antikörper gegen plazentaprotein 13
EP1484398A4 (fr) Antigene de gliome humain d'origine testiculaire
GB9911287D0 (en) Self-assembling protein structures
NO20033277D0 (no) Modifisert bitumenblanding
EP1354947A4 (fr) Nouveau polypeptide
EP1404807A4 (fr) 20 proteines humaines secretees
DE60036651D1 (de) Sericin enthaltende Nagelzusammensetzung
AU5603201A (en) Co-expression of recombinant proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030425

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060522

17Q First examination report despatched

Effective date: 20081124

GRAC Information related to communication of intention to grant a patent modified

Free format text: ORIGINAL CODE: EPIDOSCIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100720